CD109 and ovarian carcinoma: In a study by Kim et al., the surface glycoprotein CD109 was reported to be an ovarian cancer biomarker as its concentration elevated in both soluble and sEV-associated forms, validated in ovarian cancer stem cell spheroids and patient samples using WB (Kim et al., 2024).